Silo Pharma Faces Delisting Notice
Ticker: SILO · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, listing-standards
TL;DR
Silo Pharma got a delisting warning, stock might be delisted soon.
AI Summary
Silo Pharma, Inc. filed an 8-K on December 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective December 24, 2025. The company, formerly known as Uppercut Brands, Inc., is incorporated in Nevada and has its principal executive offices in Sarasota, Florida.
Why It Matters
This filing indicates potential issues with Silo Pharma's compliance with stock exchange listing requirements, which could lead to the stock being delisted.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading viability.
Key Players & Entities
- Silo Pharma, Inc. (company) — Registrant
- December 24, 2025 (date) — Earliest event reported
- December 29, 2025 (date) — Date of report
- Uppercut Brands, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Sarasota, FL (location) — Principal executive offices
FAQ
What specific listing rule or standard did Silo Pharma, Inc. fail to meet?
The filing does not specify the exact rule or standard that Silo Pharma, Inc. failed to meet, only that a notice of delisting or failure to satisfy a continued listing rule or standard was issued.
When was the notice of delisting or failure to meet listing standards issued?
The notice was issued as of December 24, 2025, and the report was filed on December 29, 2025.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated December 24, 2025.
What was Silo Pharma, Inc. formerly known as?
Silo Pharma, Inc. was formerly known as Uppercut Brands, Inc.
Where are Silo Pharma, Inc.'s principal executive offices located?
Silo Pharma, Inc.'s principal executive offices are located at 677 N. Washington Boulevard, Sarasota, FL 34236.
Filing Stats: 833 words · 3 min read · ~3 pages · Grade level 14.2 · Accepted 2025-12-29 09:04:03
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
- $1.00 — ties to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810
Filing Documents
- ea0271073-8k_silopharma.htm (8-K) — 27KB
- 0001213900-25-125838.txt ( ) — 187KB
- silo-20251224.xsd (EX-101.SCH) — 3KB
- silo-20251224_lab.xml (EX-101.LAB) — 33KB
- silo-20251224_pre.xml (EX-101.PRE) — 22KB
- ea0271073-8k_silopharma_htm.xml (XML) — 3KB
01 Notice of
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in a Current Report on Form 8-K filed by Silo Pharma, Inc. (the "Company") on June 27, 2025, the Company received a notification (the "Notification Letter") from The Nasdaq Stock Market, LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Company initially had 180 calendar days, or until by December 24, 2025, to regain compliance with the minimum bid price requirement. The Company was unable to regain compliance with the minimum bid price requirement by December 24, 2025. On December 24, 2025, the Company received a letter (the "Extension Notice") from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until June 22, 2026, to regain compliance with the minimum bid price requirement. Nasdaq's determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Extension Notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market and, at this time, the Company's common s
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: December 29, 2025 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer 2